Physician profile
Harsukh J Savalia
NPI 1821204900
$9,191.69
in general payments reported to CMS, 2019-2025
16 companies · $868 in 2025
The $868 reported for 2025 was more than what 82% of Geriatric Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,691 · 2020: $702 · 2021: $632 · 2022: $135 · 2023: $1,969 · 2024: $2,194 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,031.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,520.38 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,186.42 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,154.78 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,134.88 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $730.20 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $727.81 | 2019-2024 | Austedo Xr, Uzedy |
| Allergan, INC. | $720.97 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $571.89 | 2023-2024 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $485.69 | 2019-2024 | Lybalvi, Aristada, Aristada Initio |
| Axsome Therapeutics, INC. | $377.00 | 2022-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $236.24 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $133.26 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $118.40 | 2024 | Ingrezza |
| Eisai INC. | $48.73 | 2021 | |
| Tris Pharma INC | $30.00 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $15.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsukh Savalia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.